{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T11:32:30Z","timestamp":1791718350773,"version":"4.3.4"},"reference-count":57,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1053\/j.ajkd.2021.09.017","type":"journal-article","created":{"date-parts":[[2021,11,7]],"date-time":"2021-11-07T17:18:28Z","timestamp":1636305508000},"page":"868-876","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":71,"title":["Recent and Emerging Therapies for Iron Deficiency in Anemia of CKD: A Review"],"prefix":"10.1053","volume":"79","author":[{"given":"Jonathan W.","family":"Bazeley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay B.","family":"Wish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1053\/j.ajkd.2021.09.017_bib1","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1053\/j.seminhematol.2009.06.004","article-title":"Recycling iron in normal and pathological states","volume":"46","author":"Beaumont","year":"2009","journal-title":"Semin Hematol"},{"issue":"5","key":"10.1053\/j.ajkd.2021.09.017_bib2","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/bjh.12311","article-title":"Guideline for the laboratory diagnosis of functional iron deficiency","volume":"161","author":"Thomas","year":"2013","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1053\/j.ajkd.2021.09.017_bib3","first-page":"1947","article-title":"Decreased iron intake parallels rising iron deficiency anemia and related mortality rates in the US population","volume":"151","author":"Sun","year":"2021","journal-title":"J\u00a0Nutr"},{"issue":"3","key":"10.1053\/j.ajkd.2021.09.017_bib4","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.cell.2016.12.034","article-title":"A\u00a0red carpet for iron metabolism","volume":"168","author":"Muckenthaler","year":"2017","journal-title":"Cell"},{"issue":"3","key":"10.1053\/j.ajkd.2021.09.017_bib5","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1159\/000183074","article-title":"Evaluation of iron status in patients on chronic hemodialysis: relative usefulness of bone marrow hemosiderin, serum ferritin, transferrin saturation, mean corpuscular volume and red cell protoporphyrin","volume":"35","author":"Moreb","year":"1983","journal-title":"Nephron"},{"issue":"8","key":"10.1053\/j.ajkd.2021.09.017_bib6","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/jcp.2009.064451","article-title":"Improved method for assessing iron stores in the bone marrow","volume":"62","author":"Phiri","year":"2009","journal-title":"J\u00a0Clin Pathol"},{"issue":"3","key":"10.1053\/j.ajkd.2021.09.017_bib7","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1681\/ASN.2019020213","article-title":"Iron deficiency in chronic kidney disease: updates on pathophysiology, diagnosis, and treatment","volume":"31","author":"Batchelor","year":"2020","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2021.09.017_bib8","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.kint.2021.03.020","article-title":"Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference","volume":"99","author":"Babitt","year":"2021","journal-title":"Kidney Int"},{"issue":"suppl 1","key":"10.1053\/j.ajkd.2021.09.017_bib9","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.2215\/CJN.01490506","article-title":"Assessing iron status: beyond serum ferritin and transferrin saturation","volume":"1","author":"Wish","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2021.09.017_bib10","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/kisup.2012.34","article-title":"KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Chapter 2: use of iron to treat anemia in CKD","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"10.1053\/j.ajkd.2021.09.017_bib11","first-page":"CD007857","article-title":"Parenteral versus oral iron therapy for adults and children with chronic kidney disease","volume":"1","author":"Albaramki","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1053\/j.ajkd.2021.09.017_bib12","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1053\/j.ajkd.2016.04.018","article-title":"Intravenous versus oral iron supplementation for the treatment of anemia in CKD: an updated systematic review and meta-analysis","volume":"68","author":"Shepshelovich","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"suppl 1","key":"10.1053\/j.ajkd.2021.09.017_bib13","first-page":"S78","article-title":"Iron deficiency anemia in chronic kidney disease: uncertainties and cautions","volume":"21","author":"Agarwal","year":"2017","journal-title":"Hemodial Int"},{"issue":"6","key":"10.1053\/j.ajkd.2021.09.017_bib14","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1681\/ASN.2016101053","article-title":"Effects of ferric citrate in patients with nondialysis-dependent CKD and iron deficiency anemia","volume":"28","author":"Fishbane","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"11","key":"10.1053\/j.ajkd.2021.09.017_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0188712","article-title":"Safety and efficacy of ferric citrate in patients with nondialysis-dependent chronic kidney disease","volume":"12","author":"Chertow","year":"2017","journal-title":"PLoS One"},{"issue":"6","key":"10.1053\/j.ajkd.2021.09.017_bib16","doi-asserted-by":"crossref","first-page":"E154","DOI":"10.1002\/ajh.25088","article-title":"Hemoglobin response to ferric citrate in patients with nondialysis-dependent chronic kidney disease and iron deficiency anemia","volume":"93","author":"Pergola","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1053\/j.ajkd.2021.09.017_bib17","doi-asserted-by":"crossref","first-page":"846824","DOI":"10.1100\/2012\/846824","article-title":"Ferrous versus ferric oral iron formulations for the treatment of iron deficiency: a clinical overview","volume":"2012","author":"Santiago","year":"2012","journal-title":"ScientificWorldJournal"},{"issue":"8","key":"10.1053\/j.ajkd.2021.09.017_bib18","first-page":"807","article-title":"Iron formulations in pediatric practice","volume":"41","author":"Nagpal","year":"2004","journal-title":"Indian Pediatr"},{"issue":"9","key":"10.1053\/j.ajkd.2021.09.017_bib19","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.2215\/CJN.15291219","article-title":"Effect of ferric citrate versus ferrous sulfate on iron and phosphate parameters in patients with iron deficiency and CKD: a randomized trial","volume":"15","author":"Womack","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2021.09.017_bib20","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1681\/ASN.2014020212","article-title":"Ferric citrate controls phosphorus and delivers iron in patients on dialysis","volume":"26","author":"Lewis","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2021.09.017_bib21","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1586\/14737167.2015.995169","article-title":"Phosphorus binding with ferric citrate is associated with fewer hospitalizations and reduced hospitalization costs","volume":"15","author":"Rodby","year":"2015","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"3","key":"10.1053\/j.ajkd.2021.09.017_bib22","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s40268-015-0103-y","article-title":"Ferric citrate, an iron-based phosphate binder, reduces health care costs in patients on dialysis based on randomized clinical trial data","volume":"15","author":"Rodby","year":"2015","journal-title":"Drugs R D"},{"issue":"7","key":"10.1053\/j.ajkd.2021.09.017_bib23","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1093\/ndt\/gfy318","article-title":"Effect of ferric citrate on serum phosphate and fibroblast growth factor 23 among patients with nondialysis-dependent chronic kidney disease: path analyses","volume":"34","author":"Block","year":"2019","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1053\/j.ajkd.2021.09.017_bib24","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/bcp.14396","article-title":"Ferric citrate in the management of hyperphosphataemia and iron deficiency anaemia: a meta-analysis in patients with chronic kidney disease","volume":"87","author":"Choi","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1053\/j.ajkd.2021.09.017_bib25","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1053\/j.ackd.2019.05.002","article-title":"Novel oral iron therapies for iron deficiency anemia in chronic kidney disease","volume":"26","author":"Pergola","year":"2019","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1053\/j.ajkd.2021.09.017_bib26","doi-asserted-by":"crossref","unstructured":"Pergola PE, Kopyt NP. Oral ferric maltol for the treatment of iron-deficiency anemia in patients with CKD: a randomized trial and open-label extension. Am J Kidney Dis. Published online May 3, 2020. doi:10.1053\/j.ajkd.2021.03.020","DOI":"10.1053\/j.ajkd.2021.03.020"},{"issue":"4","key":"10.1053\/j.ajkd.2021.09.017_bib28","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3390\/ph11040097","article-title":"Sucrosomial(\u00ae) iron: a new generation iron for improving oral supplementation","volume":"11","author":"G\u00f3mez-Ram\u00edrez","year":"2018","journal-title":"Pharmaceuticals (Basel)"},{"issue":"4","key":"10.1053\/j.ajkd.2021.09.017_bib29","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1093\/ndt\/gfu357","article-title":"Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: a randomized trial","volume":"30","author":"Pisani","year":"2015","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"10.1053\/j.ajkd.2021.09.017_bib30","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/ajh.21154","article-title":"Intravenous iron: from anathema to standard of care","volume":"83","author":"Auerbach","year":"2008","journal-title":"Am J Hematol"},{"key":"10.1053\/j.ajkd.2021.09.017_bib31","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1182\/blood.V1.2.129.129","article-title":"Observations on the effect of massive doses of iron given intravenously to patients with hypochromic anemia","volume":"1","author":"Goetsch","year":"1946","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.ajkd.2021.09.017_bib32","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/sdi.12732","article-title":"When should iron supplementation in dialysis patients be avoided, minimized or withdrawn?","volume":"32","author":"Rostoker","year":"2019","journal-title":"Semin Dial"},{"issue":"12","key":"10.1053\/j.ajkd.2021.09.017_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0050295","article-title":"Intravenous ferric chloride hexahydrate supplementation induced endothelial dysfunction and increased cardiovascular risk among hemodialysis patients","volume":"7","author":"Kuo","year":"2012","journal-title":"PLoS One"},{"issue":"4","key":"10.1053\/j.ajkd.2021.09.017_bib34","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/ki.2014.114","article-title":"Association between hemoglobin variability, serum ferritin levels, and adverse events\/mortality in maintenance hemodialysis patients","volume":"86","author":"Kuragano","year":"2014","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ajkd.2021.09.017_bib35","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/ki.2014.275","article-title":"Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality","volume":"87","author":"Bailie","year":"2015","journal-title":"Kidney Int"},{"issue":"7","key":"10.1053\/j.ajkd.2021.09.017_bib36","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1080\/14740338.2021.1912010","article-title":"Newer formulations of intravenous iron: a review of their chemistry and key safety aspects - hypersensitivity, hypophosphatemia, and cardiovascular safety","volume":"20","author":"Blumenstein","year":"2021","journal-title":"Expert Opin Drug Saf"},{"issue":"6","key":"10.1053\/j.ajkd.2021.09.017_bib37","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1097\/MNH.0000000000000263","article-title":"Safety of intravenous iron use in chronic kidney disease","volume":"25","author":"Kalra","year":"2016","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"1","key":"10.1053\/j.ajkd.2021.09.017_bib39","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/phar.1525","article-title":"Effects of an accelerated intravenous iron regimen in hospitalized patients with advanced heart failure and iron deficiency","volume":"35","author":"Reed","year":"2015","journal-title":"Pharmacotherapy"},{"issue":"11","key":"10.1053\/j.ajkd.2021.09.017_bib41","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1002\/ajh.23534","article-title":"Safety and efficacy of total dose infusion of 1,020 mg of ferumoxytol administered over 15 min","volume":"88","author":"Auerbach","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1053\/j.ajkd.2021.09.017_bib42","doi-asserted-by":"crossref","DOI":"10.1177\/20406207211006022","article-title":"Safety and efficacy of a single total dose infusion (1020mg)of ferumoxytol","volume":"12","author":"Khan","year":"2021","journal-title":"Ther Adv Hematol"},{"key":"10.1053\/j.ajkd.2021.09.017_bib45","unstructured":"ClinicalTrials.gov. Efficacy and safety of intravenous ferric carboxymaltose (FCM) in patients with iron deficiency anemia (IDA). Updated February 20, 2018. Accessed May 16, 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT00982007."},{"issue":"4","key":"10.1053\/j.ajkd.2021.09.017_bib46","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1093\/ndt\/gft251","article-title":"Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial","volume":"29","author":"Onken","year":"2014","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"10.1053\/j.ajkd.2021.09.017_bib47","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1093\/ndt\/gfu201","article-title":"FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia","volume":"29","author":"Macdougall","year":"2014","journal-title":"Nephrol Dial Transplant"},{"issue":"9","key":"10.1053\/j.ajkd.2021.09.017_bib49","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/ajh.25564","article-title":"A\u00a0prospective, multi-center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON-IDA trial","volume":"94","author":"Auerbach","year":"2019","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1053\/j.ajkd.2021.09.017_bib50","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/ndt\/gfaa011","article-title":"Safety and efficacy of iron isomaltoside 1000\/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial","volume":"36","author":"Bhandari","year":"2021","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"10.1053\/j.ajkd.2021.09.017_bib51","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/trf.15837","article-title":"Clinical data for intravenous iron - debunking the hype around hypersensitivity","volume":"60","author":"Achebe","year":"2020","journal-title":"Transfusion"},{"issue":"23","key":"10.1053\/j.ajkd.2021.09.017_bib52","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.124486","article-title":"Randomized trial of intravenous iron-induced hypophosphatemia","volume":"3","author":"Wolf","year":"2018","journal-title":"JCI Insight"},{"issue":"5","key":"10.1053\/j.ajkd.2021.09.017_bib53","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jama.2019.22450","article-title":"Effects of iron isomaltoside vs ferric carboxymaltose on hypophosphatemia in iron-deficiency anemia: two randomized clinical trials","volume":"323","author":"Wolf","year":"2020","journal-title":"JAMA"},{"issue":"2","key":"10.1053\/j.ajkd.2021.09.017_bib54","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1080\/17474086.2020.1709437","article-title":"Indirect methods of comparison of the safety of ferric derisomaltose, iron sucrose and ferric carboxymaltose in the treatment of iron deficiency anemia","volume":"13","author":"Pollock","year":"2020","journal-title":"Expert Rev Hematol"},{"key":"10.1053\/j.ajkd.2021.09.017_bib55","doi-asserted-by":"crossref","first-page":"100862","DOI":"10.1016\/j.mam.2020.100862","article-title":"Intravenous iron supplementation therapy","volume":"75","author":"Schaefer","year":"2020","journal-title":"Mol Aspects Med"},{"key":"10.1053\/j.ajkd.2021.09.017_bib56","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2147\/TCRM.S243462","article-title":"Hypophosphatemia associated with intravenous iron therapies for iron deficiency anemia: a systematic literature review","volume":"16","author":"Glaspy","year":"2020","journal-title":"Ther Clin Risk Manag"},{"key":"10.1053\/j.ajkd.2021.09.017_bib57","doi-asserted-by":"crossref","DOI":"10.7573\/dic.2020-11-3","article-title":"Hypophosphataemia, fibroblast growth factor 23 and third-generation intravenous iron compounds: a narrative review","volume":"10","author":"Kassianides","year":"2021","journal-title":"Drugs Context"},{"issue":"1","key":"10.1053\/j.ajkd.2021.09.017_bib58","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41581-019-0189-5","article-title":"FGF23 at the crossroads of phosphate, iron economy and erythropoiesis","volume":"16","author":"Edmonston","year":"2020","journal-title":"Nat Rev Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2021.09.017_bib59","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/MNH.0000000000000329","article-title":"Iron-induced hypophosphatemia: an emerging complication","volume":"26","author":"Zoller","year":"2017","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"3","key":"10.1053\/j.ajkd.2021.09.017_bib60","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.3390\/ijms22031008","article-title":"Iron therapy in chronic kidney disease: days of future past","volume":"22","author":"Lee","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"12","key":"10.1053\/j.ajkd.2021.09.017_bib61","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1093\/ndt\/gfv277","article-title":"Ferric pyrophosphate citrate (Triferic\u2122) administration via the dialysate maintains hemoglobin and iron balance in chronic hemodialysis patients","volume":"30","author":"Fishbane","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2021.09.017_bib62","doi-asserted-by":"crossref","unstructured":"Pratt RD. Ferric pyrophosphate citrate injection: no clinical drug interaction with unfractionated heparin in hemodialysis patients [abstract]. In: Kidney Week 2020 Reimagined Abstracts. American Society of Nephrology; 2020:B6-B7. Abstract PO2631.","DOI":"10.1681\/ASN.20203110S1B6b"},{"issue":"6","key":"10.1053\/j.ajkd.2021.09.017_bib64","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1365-2362.2009.02130.x","article-title":"Physicochemical properties of ferumoxytol, a new intravenous iron preparation","volume":"39","author":"Balakrishnan","year":"2009","journal-title":"Eur J Clin Invest"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638621009550?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638621009550?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T03:43:39Z","timestamp":1759463019000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638621009550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":57,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S0272638621009550"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2021.09.017","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent and Emerging Therapies for Iron Deficiency in Anemia of CKD: A Review","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2021.09.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}